Curanex Pharmaceuticals Inc
CURX
$0.44
$0.037.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 193.57% | 30.54% | 71.45% | 403.15% | 93,200.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 919.61% | 30.54% | 71.45% | 403.15% | 93,200.00% |
| Operating Income | -919.61% | -30.54% | -71.45% | -403.15% | -93,200.00% |
| Income Before Tax | -946.16% | -36.43% | -71.57% | -980.31% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -946.16% | -36.43% | -71.57% | -980.31% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -946.16% | -36.43% | -71.57% | -980.31% | -- |
| EBIT | -919.61% | -30.54% | -71.45% | -403.15% | -93,200.00% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 1.84% | 86.41% | 95.74% | 72.99% | -- |
| Normalized Basic EPS | 1.69% | 86.09% | 95.69% | 87.88% | -- |
| EPS Diluted | 1.84% | 86.41% | 95.74% | 72.99% | -- |
| Normalized Diluted EPS | 1.69% | 86.09% | 95.69% | 87.88% | -- |
| Average Basic Shares Outstanding | 966.65% | 900.00% | 3,900.00% | 3,913.07% | 300.00% |
| Average Diluted Shares Outstanding | 966.65% | 900.00% | 3,900.00% | 3,913.07% | 300.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |